Lung Cancer, Non-Small Cell Clinical Trial
Official title:
An Open-label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-line Treatment of Subjects With Predominantly Non-squamous Cell Stage IIIBwet/IV Non-small Cell Lung Cancer
The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05598528 -
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
|
||
| Completed |
NCT03836469 -
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
|
||
| Completed |
NCT01772225 -
NSCLC Burden of Illness Study
|
N/A | |
| Completed |
NCT01362296 -
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01460472 -
Immunotherapy With Racotumomab in Advanced Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03803137 -
Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection
|
N/A | |
| Completed |
NCT00528281 -
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
|
Phase 1 | |
| Not yet recruiting |
NCT04592666 -
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00480025 -
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT05784142 -
Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)
|
Phase 2 | |
| Active, not recruiting |
NCT04475939 -
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
|
Phase 3 | |
| Withdrawn |
NCT01938456 -
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
|
Phase 1 | |
| Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
| Recruiting |
NCT05565378 -
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04986670 -
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
|
N/A | |
| Completed |
NCT00367679 -
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00073008 -
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04581824 -
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT00619424 -
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04940936 -
Shared Decision Making on Radiation Dose for Lung Malignancies
|
N/A |